Format

Send to

Choose Destination
Clin Pharmacol Ther. 2014 Sep;96(3):324-39. doi: 10.1038/clpt.2014.126. Epub 2014 Jun 12.

Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications.

Author information

1
1] Pharmacogenomics Laboratory, Centre Hospitalier Universitaire (CHU) de Québec Research Center, Québec, Canada; Faculty of Pharmacy, Laval University, Québec, Canada [2] Pharmacogenomics Laboratory, CHU de Québec Research Center, Québec, Canada.
2
1] Pharmacogenomics Laboratory, Centre Hospitalier Universitaire (CHU) de Québec Research Center, Québec, Canada; Faculty of Pharmacy, Laval University, Québec, Canada [2] Faculty of Medicine, Laval University, Québec, Canada.

Abstract

Glucuronidation by uridine diphospho-glucuronosyltransferase enzymes (UGTs) is a major phase II biotransformation pathway and, complementary to phase I metabolism and membrane transport, one of the most important cellular defense mechanisms responsible for the inactivation of therapeutic drugs, other xenobiotics, and endogenous molecules. Interindividual variability in UGT pathways is significant and may have profound pharmacological and toxicological implications. Several genetic and genomic processes underlie this variability and are discussed in relation to drug metabolism and diseases such as cancer.

PMID:
24922307
DOI:
10.1038/clpt.2014.126
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley Icon for Corpus, Universite Laval
Loading ...
Support Center